1: Shen Y, Ai J, Lin N, Zhang H, Li Y, Wang H, Wang S, Wang Z, Li T, Sun F, Fan Z, Li L, Lu Y, Meng X, Xiao H, Hu H, Ling Y, Li F, Li H, Xi C, Gu L, Zhang W, Fan X. An Open, Prospective Cohort Study of VV116 in Chinese Participants Infected with SARS-CoV-2 Omicron Variants. Emerg Microbes Infect. 2022 May 17:1-22. doi: 10.1080/22221751.2022.2078230. Epub ahead of print. PMID: 35579892. 2: Zhang R, Zhang Y, Zheng W, Shang W, Wu Y, Li N, Xiong J, Jiang H, Shen J, Xiao G, Xie Y, Zhang L. Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model. Signal Transduct Target Ther. 2022 Apr 16;7(1):123. doi: 10.1038/s41392-022-00963-7. PMID: 35429988; PMCID: PMC9012943. 3: Qian HJ, Wang Y, Zhang MQ, Xie YC, Wu QQ, Liang LY, Cao Y, Duan HQ, Tian GH, Ma J, Zhang ZB, Li N, Jia JY, Zhang J, Aisa HA, Shen JS, Yu C, Jiang HL, Zhang WH, Wang Z, Liu GY. Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects. Acta Pharmacol Sin. 2022 Mar 16:1–9. doi: 10.1038/s41401-022-00895-6. Epub ahead of print. PMID: 35296780; PMCID: PMC8924727. 4: Wu CR, Yin WC, Jiang Y, Xu HE. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. Acta Pharmacol Sin. 2022 Jan 20:1–13. doi: 10.1038/s41401-021-00851-w. Epub ahead of print. PMID: 35058587; PMCID: PMC8771608. 5: Xie Y, Yin W, Zhang Y, Shang W, Wang Z, Luan X, Tian G, Aisa HA, Xu Y, Xiao G, Li J, Jiang H, Zhang S, Zhang L, Xu HE, Shen J. Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2. Cell Res. 2021 Nov;31(11):1212-1214. doi: 10.1038/s41422-021-00570-1. Epub 2021 Sep 28. PMID: 34584244; PMCID: PMC8477624.
